Mackenzie Financial Corp Vertex Pharmaceuticals Inc Transaction History

Mackenzie Financial Corp

$66.8 Billion
Q3 2024

A detailed history of Mackenzie Financial Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mackenzie Financial Corp holds 68,692 shares of VRTX stock, worth $31 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

68,692

Previous 84,634 18.84%

Holding current value

$31 Million

Previous $39.7 Million 19.47%

% of portfolio

0.05%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$460.0 - $505.78 $7.33 Million - $8.06 Million	-15,942 Reduced 18.84%	68,692 $31.9 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $3.07 Million - $3.8 Million	-7,818 Reduced 8.46%	84,634 $39.7 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $2.29 Million - $2.51 Million	5,625 Added 6.48%	92,452 $38.6 Million
Q4 2023 Jan 30, 2024	BUY	$343.0 - $410.68 $1.32 Million - $1.58 Million	3,856 Added 4.65%	86,827 $35.3 Million
Q3 2023 Oct 25, 2023	SELL	$338.18 - $362.46 $3.29 Million - $3.52 Million	-9,719 Reduced 10.49%	82,971 $28.9 Million
Q2 2023 Aug 03, 2023	SELL	$314.42 - $351.91 $37.2 Million - $41.7 Million	-118,393 Reduced 56.09%	92,690 $32.6 Million
Q1 2023 Apr 24, 2023	BUY	$283.23 - $323.1 $28.9 Million - $33 Million	102,181 Added 93.83%	211,083 $66.5 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $2.63 Million - $2.96 Million	-9,220 Reduced 7.81%	108,902 $31.4 Million
Q3 2022 Oct 07, 2022	BUY	$273.83 - $305.53 $7.69 Million - $8.58 Million	28,080 Added 31.19%	118,122 $34.2 Million
Q2 2022 Aug 10, 2022	SELL	$234.96 - $292.55 $2.18 Million - $2.72 Million	-9,283 Reduced 9.35%	90,042 $25.4 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $2.63 Million - $3.1 Million	11,876 Added 13.58%	99,325 $25.9 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $335,610 - $423,661	1,896 Added 2.22%	87,449 $19.2 Million
Q3 2021 Nov 08, 2021	BUY	$181.39 - $202.99 $816,799 - $914,063	4,503 Added 5.56%	85,553 $15.5 Million
Q2 2021 Aug 11, 2021	BUY	$187.49 - $221.1 $2.03 Million - $2.39 Million	10,827 Added 15.42%	81,050 $16.3 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $6.71 Million - $7.82 Million	32,402 Added 85.67%	70,223 $15.1 Million
Q4 2020 Feb 10, 2021	BUY	$207.01 - $276.09 $2.78 Million - $3.71 Million	13,435 Added 55.09%	37,821 $8.94 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $1.81 Million - $2.15 Million	7,080 Added 40.91%	24,386 $6.64 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $1.77 Million - $2.32 Million	7,852 Added 83.05%	17,306 $5.02 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $1.05 Million - $1.31 Million	5,281 Added 126.55%	9,454 $2.25 Million
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $444,448 - $596,944	2,666 Added 176.91%	4,173 $914,000
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $1,496 - $1,683	9 Added 0.6%	1,507 $255,000
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $4.86 Million - $5.62 Million	-29,512 Reduced 95.17%	1,498 $275,000
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $6.5 Million - $7.73 Million	-39,700 Reduced 56.14%	31,010 $5.7 Million
Q4 2018 Feb 06, 2019	BUY	$151.91 - $192.21 $9.96 Million - $12.6 Million	65,561 Added 1273.28%	70,710 $11.7 Million
Q3 2018 Nov 15, 2018	BUY	$167.73 - $192.74 $23,985 - $27,561	143 Added 2.86%	5,149 $992,000
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $144,408 - $168,430	991 Added 24.68%	5,006 $851,000
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $269,090 - $314,405	1,775 Added 79.24%	4,015 $654,000
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $307,507 - $348,432	2,240	2,240 $336,000

Others Institutions Holding VRTX

# of Institutions

1,721

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account

Mackenzie Financial Corp Vertex Pharmaceuticals Inc Transaction History